Longevity peptides 2026: the compounds, the evidence, and what to actually source

The longevity-peptide landscape in 2026

The "longevity peptide" cluster is more functional than strictly chemical. It groups together compounds studied for healthspan or lifespan extension, regardless of whether they are technically peptides (sequences of amino acids), small molecules, or proteins. This article maps the current state of evidence for each compound the cluster commonly refers to and links to per-compound reference pages where the deeper read lives.

The strongest evidence — rapamycin

Rapamycin is the only pharmacological intervention that has extended lifespan in every animal model it has been tested in — yeast, worms, flies, mice. The 2009 NIH Interventions Testing Program mouse study showed 9-14% lifespan extension even when treatment began at 600 days (late-middle-age). Subsequent ITP trials replicated the effect and showed dose-response curves. mTOR inhibition is the single strongest cross-species longevity signal in modern pharmacology.

Off-label human use has accelerated sharply since 2020. Typical protocols cite 5-10 mg orally once per week. The intermittent weekly dosing is chosen specifically to inhibit mTORC1 (the longevity-relevant complex) while allowing mTORC2 (whose chronic inhibition drives side effects) to recover. Human longevity outcome data is still developing — the PEARL human trial and the Dog Aging Project TRIAD canine trial are the active reads. See rapamycin vs metformin for the comparison framing most buyers actually want.

The cellular-mechanism case — NAD+ and MOTS-c

NAD+ is a coenzyme central to redox metabolism. Cellular NAD+ levels decline measurably with age, and this decline correlates with reduced sirtuin and PARP activity in published research. The hypothesis driving research-protocol interest is that restoring NAD+ levels may slow age-related metabolic dysfunction. Causal evidence in humans is still developing — most accumulated data is from NAD+ precursors (NMN, NR) rather than direct NAD+ administration. The compound has poor oral bioavailability, so administration is subcutaneous or IV.

MOTS-c is a mitochondrial-derived peptide (encoded in mitochondrial DNA rather than nuclear DNA) studied for AMPK activation, mitochondrial function, and metabolic-health outcomes. Mouse studies show improved insulin sensitivity and exercise capacity. Human trials are early-stage. The mechanism is plausible and the cellular biology is well-characterized; the lifespan-extension question is open.

The GH-axis cluster — sermorelin, CJC-1295, ipamorelin, tesamorelin

The GH axis is one of the most-studied biological systems in aging research, but the relationship between GH and lifespan is complicated. In multiple model organisms, reduced GH/IGF-1 signaling actually extends lifespan (the Laron syndrome literature is the most-cited human evidence). GH-axis peptides used in research protocols are therefore better understood as healthspan and body-composition interventions than as direct lifespan-extension agents.

Sermorelin is a 29-amino-acid synthetic GHRH analog that stimulates the pituitary to release endogenous growth hormone. Half-life is ~12 minutes; the effect comes from the resulting GH pulse rather than sustained sermorelin levels. FDA-approved in 1990 as Geref, voluntarily withdrawn in 2008, still available through 503A pharmacies.

CJC-1295 comes in two forms — DAC (long-acting, days-long half-life) and no-DAC (Modified GRF 1-29, ~30 minutes). The DAC variant produces sustained GH and IGF-1 elevation; the no-DAC variant produces a pulse. Almost always paired with ipamorelin.

Ipamorelin is the most-selective ghrelin-receptor agonist in the research-peptide pool. It stimulates GH release without significant prolactin, cortisol, or appetite effects — the selectivity that drove its replacement of older ghrelin agonists (GHRP-6, GHRP-2). See CJC-1295 vs Ipamorelin for the stack-comparison framing.

Tesamorelin is FDA-approved for HIV-associated lipodystrophy. It is the only GHRH analog in the cluster with active FDA approval. We cover the sermorelin / tesamorelin comparison at tesamorelin vs sermorelin.

The stronger-biology-but-no-drug cluster — Klotho

Klotho has unusually strong evidence for an early-stage longevity target. Mouse lifespan extension is 20-30% with overexpression. Klotho-knockout mice develop an accelerated-aging syndrome. Human cohort studies show higher Klotho correlates with longer lifespan and better cognitive performance.

The gap is the delivery mechanism. Full-length Klotho is large (>100 kDa), which makes subcutaneous and oral bioavailability a research challenge. Several biotech companies are working on small molecules or shorter peptide fragments that elevate Klotho or mimic its effects; none have yet reached late-stage human trials. A buyer looking for an immediately-administrable Klotho intervention does not yet have one.

The Khavinson-tradition cluster — epitalon and related

Epitalon is a four-amino-acid synthetic peptide developed by Vladimir Khavinson's group in Russia starting in the 1970s. Research interest centers on cell-culture telomerase activation findings and small clinical-cohort studies of mortality and circadian endpoints. The Western-research-replication base is thin. Best understood as an experimental compound within a specific research tradition rather than an evidence-replicated longevity intervention.

The Khavinson group developed a family of short peptide bioregulators — epitalon (pineal), thymalin (thymus), prostamax (prostate), and others. Epitalon is the most-cited of the family in longevity contexts.

The tissue-repair cluster — GHK-Cu

GHK-Cu is a copper-binding tripeptide studied for collagen synthesis and wound healing. Research is concentrated in dermal regeneration and skin aging rather than systemic longevity outcomes. Pickart's 2008 review (PMID 18204724) summarizes 40+ years of accumulated work. The compound is widely available in both research-peptide and cosmetic-grade forms.

Where buyers actually source longevity peptides

Three structurally different channels with different legal and quality frames.

Research-peptide vendors sell research-grade material with COAs at the lowest price point. No FDA-approved indication, no prescriber requirement, RUO labeling. Per-vendor quality varies; see our vendor audit pages. The Kovera Labs vendor leaderboard ranks the publishing pattern across 29 vendors.

503A compounding pharmacies sell prescriber-routed compounded formulations for specific indications. The legal frame is "personalized compounding" under FDA's 503A rules. Post-shortage scrutiny is currently the headline regulatory question. See our compounding pharmacy audits.

Off-label prescribers can prescribe FDA-approved drugs (rapamycin is the main example) for non-indicated longevity use. The drug is real pharmaceutical-grade material; the indication is doctor's discretion. This is the channel longevity-medicine physicians like Peter Attia describe in their public protocols.

Related reading

• Rapamycin vs metformin — the two longevity-drug candidates compared.
• Tesamorelin vs Sermorelin — GHRH analog comparison.
• CJC-1295 vs Ipamorelin — the most-paired research-peptide stack.
• Best longevity telehealth platforms 2026 — the audit-tier read on the compounding-pharmacy channel.
• BPC-157 and TB-500 literature read — healing-peptide cluster.

Sources

• Harrison DE et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009.
• Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science 2008.
• Khavinson VK group. Peptide regulation of pineal-gland function. Bull Exp Biol Med 2003.
• Kuro-o M et al. Mutation of the mouse klotho gene leads to a syndrome resembling aging. Nature 1997.
• Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metabolism 2015.
• NIH Interventions Testing Program (ITP) — annual lifespan-extension trial publications.